Background:
The recent COVID-19 (coronavirus disease 2019) pandemic triggered research
on the development of new vaccines/drugs, repurposing of clinically approved drugs, and
assessment of natural anti-COVID-19 compounds. Based on the gender difference in the severity
of the disease, such as a higher number of men hospitalized and in intense care units, variations in
sex hormones have been predicted to play a role in disease susceptibility. Cell surface receptors
(Angiotensin-Converting Enzyme 2; ACE2 and a connected transmembrane protease serine 2-
TMPSS2) are upregulated by androgens. Conversely, androgen antagonists have also been shown
to lower ACE2 levels, implying their usefulness in COVID-19 management.
Objective:
In this study, we performed computational and cell-based assays to investigate the anti--
COVID-19 potential of Withaferin-A and Caffeic acid phenethyl ester, natural compounds from
Withania somnifera and honeybee propolis, respectively.
Methods:
Structure-based computational approach was adopted to predict binding stability, interactions,
and dynamics of the two test compounds to three target proteins (androgen receptor,
ACE2, and TMPRSS2). Further, in vitro, cell-based experimental approaches were used to investigate
the effect of compounds on target protein expression and SARS-CoV-2 replication.
Results:
Computation and experimental analyses revealed that (i) CAPE, but not Wi-A, can act as
androgen antagonist and hence inhibit the transcriptional activation function of androgen receptor,
(ii) while both Wi-A and CAPE could interact with ACE2 and TMPRSS2, Wi-A showed higher
binding affinity, and (iii) combination of Wi-A and CAPE (Wi-ACAPE) caused strong downregulation
of ACE2 and TMPRSS2 expression and inhibition of virus infection.
Conclusion:
Wi-A and CAPE possess multimodal anti-COVID-19 potential, and their combination
(Wi-ACAPE) is expected to provide better activity and hence warrant further attention in the
laboratory and clinic.